# Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

> **NCT06138561** · — · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 180 (estimated)

## Conditions studied

- Bladder Cancer
- Metastatic Bladder Cancer
- Unresectable Bladder Carcinoma
- Urothelial Carcinoma

## Interventions

- **BEHAVIORAL:** Geriatric-8 Survey
- **BEHAVIORAL:** National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)
- **BEHAVIORAL:** Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)

## Key facts

- **NCT ID:** NCT06138561
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138561, "Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06138561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*